Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia

Formulary

Volumn 40, Issue 9, 2005, Pages 298-303

  Frei, Christopher R ^a,b   Burgess, David S ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; LEVOFLOXACIN; MACROLIDE;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; FEMALE; HIGH RISK PATIENT; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT; PATIENT CARE; SURVIVAL;

EID: 25444507947     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820-837.
2. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med. 2002;166:717-723.
3. Lave JR, Fine MJ, Sankey SS, et al. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. J Gen Intern Med. 1996;11:415-421.
4. Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest. 2002;122: 1271-1279.
5. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med. 2001;111:367-374.
6. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med. 2000;109:378-385.
7. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther. 1999;6:217-222.
8. Rhew DC, Hackner D, Henderson L, et al. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest. 1998;113:142-146.
9. Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med. 1998;92:1032-1039.
10. Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient i.v. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest. 1996;110:965-971.
11. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis. 1995;22:219-223.
12. Merchant S, Mullins CD, Shih Y-CT. Factors associated with hospitalization costs for patients with community acquired pneumonia. Clin Ther. 2003;25:593-610.
13. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
14. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
15. Bartlett JG, Dowell SF, Mandell LA, et al, for the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
16. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123:1503-1511.
17. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001;119:1420-1426.
18. Burgess DS, Lewis JS II. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther. 2000;22: 872-878.
19. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 2000;34:446-452.
20. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159:2562-2572.
21. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest. 2001;119:1439-1448.
22. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399-1408.
23. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273-1276.
24. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452-1457.
25. Nicolau D. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J Antimicrob Chemother. 2002;50(Suppl 1):61-70.
26. McGowan JE Jr. Economic impact of antimicrobial resistance. Emerg Infect Dis. 2001;7:286-292.
27. Howard D, Cordell R, McGowan JE Jr, et al. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention Emory Workshop. Clin Infect Dis. 2001;33: 1573-1578.